“We believe there is still an unmet need for advanced topical treatment for patients with mild to moderate eczema,” said Robb Knie, CEO of Hoth Therapeutics, “We are satisfied with the speed at which Part A Cohort 1 of our clinical trial has achieved full recruitment and we look forward to announcing the initial effects of this trial by the end of this year. We continue our project to provide patient-centered treatments at the clinic and get a better quality of life in multiple directions. “
About Hoth Therapeutics, Inc.